Lei Huo
YOU?
Author Swipe
View article: Early tumor volume reduction by breast DCE MRI predicts pathologic complete response to neoadjuvant therapy in triple negative breast cancer
Early tumor volume reduction by breast DCE MRI predicts pathologic complete response to neoadjuvant therapy in triple negative breast cancer Open
View article: Supplementary Figure S11 from An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples during Neoadjuvant Chemotherapy
Supplementary Figure S11 from An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples during Neoadjuvant Chemotherapy Open
Subclonal architecture of longitudinal patient and PDX samples
View article: Supplementary Figure S2 from An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples during Neoadjuvant Chemotherapy
Supplementary Figure S2 from An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples during Neoadjuvant Chemotherapy Open
Histological comparison of patient and PDX samples from longitudinal sets
View article: Supplementary Table S2 from An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples during Neoadjuvant Chemotherapy
Supplementary Table S2 from An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples during Neoadjuvant Chemotherapy Open
Summary of available genomic and transcriptomic data
View article: Data from An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples during Neoadjuvant Chemotherapy
Data from An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples during Neoadjuvant Chemotherapy Open
Triple-negative breast cancer (TNBC) that fails to respond to neoadjuvant chemotherapy (NACT) can be lethal. Developing effective strategies to eradicate chemoresistant disease requires experimental models that recapitulate the heterogenei…
View article: Supplementary Figure S5 from An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples during Neoadjuvant Chemotherapy
Supplementary Figure S5 from An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples during Neoadjuvant Chemotherapy Open
Association of tumor characteristics with take rate and PDX model growth
View article: Supplementary Figure S7 from An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples during Neoadjuvant Chemotherapy
Supplementary Figure S7 from An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples during Neoadjuvant Chemotherapy Open
Subtype coefficients for each PDX models underscores TNBC heterogeneity
View article: Supplementary Figure S8 from An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples during Neoadjuvant Chemotherapy
Supplementary Figure S8 from An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples during Neoadjuvant Chemotherapy Open
Subtype coefficients for longitudinal PDX models
View article: Supplementary Table S3 from An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples during Neoadjuvant Chemotherapy
Supplementary Table S3 from An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples during Neoadjuvant Chemotherapy Open
Summary of available data for longitudinal PDX sets
View article: Supplementary Figure S12 from An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples during Neoadjuvant Chemotherapy
Supplementary Figure S12 from An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples during Neoadjuvant Chemotherapy Open
RPPA analysis of matched PDX sets
View article: Supplementary Table S4 from An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples during Neoadjuvant Chemotherapy
Supplementary Table S4 from An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples during Neoadjuvant Chemotherapy Open
Normalized log2-transformed RPPA data
View article: Supplementary Table S1 from An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples during Neoadjuvant Chemotherapy
Supplementary Table S1 from An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples during Neoadjuvant Chemotherapy Open
PDX characteristics and associated patient demographics
View article: Supplementary Figure S10 from An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples during Neoadjuvant Chemotherapy
Supplementary Figure S10 from An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples during Neoadjuvant Chemotherapy Open
Summary of conservation scores between patient and PDX samples
View article: Supplementary Figure S1 from An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples during Neoadjuvant Chemotherapy
Supplementary Figure S1 from An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples during Neoadjuvant Chemotherapy Open
Histological comparison of patient and PDX samples from longitudinal sets
View article: Supplementary Figure S3 from An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples during Neoadjuvant Chemotherapy
Supplementary Figure S3 from An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples during Neoadjuvant Chemotherapy Open
Histological comparison of patient and PDX samples from longitudinal sets
View article: Supplementary Figure S6 from An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples during Neoadjuvant Chemotherapy
Supplementary Figure S6 from An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples during Neoadjuvant Chemotherapy Open
Copy number summary of PDX collection
View article: Supplementary Figure S9 from An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples during Neoadjuvant Chemotherapy
Supplementary Figure S9 from An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples during Neoadjuvant Chemotherapy Open
Inclusion of murine stromal reads in PDX model gene expression
View article: Supplementary Figure S4 from An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples during Neoadjuvant Chemotherapy
Supplementary Figure S4 from An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples during Neoadjuvant Chemotherapy Open
Histological comparison of patient and PDX samples from longitudinal sets
View article: Exercise interventions for pulmonary function impairment: rehabilitation strategies from the acute phase to long-term sequelae
Exercise interventions for pulmonary function impairment: rehabilitation strategies from the acute phase to long-term sequelae Open
Pulmonary function impairment, as a major global public health concern, significantly affects respiratory function, quality of life and mortality. Its pathological features include impaired gas exchange, reduced exercise tolerance, and chr…
View article: Predictive biomarkers for immune checkpoint inhibitor (ICI) and poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi) in advanced-stage breast carcinoma
Predictive biomarkers for immune checkpoint inhibitor (ICI) and poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi) in advanced-stage breast carcinoma Open
View article: Supplementary Figure SF1 from Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study
Supplementary Figure SF1 from Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study Open
Somatic mutations identified by whole exome sequencing. Oncoplot representing the most common somatic mutations assessed by whole exome sequencing (WES) in tumors obtained from patients (n = 23) at the time of diagnosis. Genes with mutatio…
View article: Supplementary Figure SF3 from Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study
Supplementary Figure SF3 from Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study Open
SUPPLEMENTARY FIGURE SF3. Box plots showing relationship between tumor mutational burden and pathological response.
View article: SUPPLEMENTARY TABLE ST2 from Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study
SUPPLEMENTARY TABLE ST2 from Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study Open
Type of Surgery and Adjuvant Therapy Received.
View article: SUPPLEMENTARY TABLE ST3 from Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study
SUPPLEMENTARY TABLE ST3 from Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study Open
Representativeness of Study Participants.
View article: Supplementary Figure SF2 from Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study
Supplementary Figure SF2 from Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study Open
SUPPLEMENTARY FIGURE SF2. Somatic mutations in genes commonly altered in TNBC. Oncoplot showing somatic mutations reported as commonly prevalent in other TNBC cohorts.
View article: SUPPLEMENTARY TABLE ST1 from Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study
SUPPLEMENTARY TABLE ST1 from Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study Open
Molecular Subtypes and Pathological Response.
View article: Deep Learning Models Based on Pretreatment MRI and Clinicopathological Data to Predict Responses to Neoadjuvant Systemic Therapy in Triple-Negative Breast Cancer
Deep Learning Models Based on Pretreatment MRI and Clinicopathological Data to Predict Responses to Neoadjuvant Systemic Therapy in Triple-Negative Breast Cancer Open
Purpose: To develop deep learning models for predicting the pathologic complete response (pCR) to neoadjuvant systemic therapy (NAST) in patients with triple-negative breast cancer (TNBC) based on pretreatment multiparametric breast MRI an…
View article: Different Intensities of Physical Activity and Risk of Male Genital Cancers: Exploring Potential Causal Relationships
Different Intensities of Physical Activity and Risk of Male Genital Cancers: Exploring Potential Causal Relationships Open
Physical activity is associated with cancer of the male genitalia. However, the genetic causality of this association remains unclear. In this study, Mendelian randomization (MR) was used to explore the potential causal relationship betwee…
View article: Quality inspection technology of solar-powered drones based on artificial intelligence
Quality inspection technology of solar-powered drones based on artificial intelligence Open
View article: An annotated biobank of triple negative breast cancer patient-derived xenografts featuring treatment-naïve and longitudinal samples throughout neoadjuvant chemotherapy
An annotated biobank of triple negative breast cancer patient-derived xenografts featuring treatment-naïve and longitudinal samples throughout neoadjuvant chemotherapy Open
SUMMARY Triple negative breast cancer (TNBC) that fails to respond to neoadjuvant chemotherapy (NACT) can be lethal. Developing effective strategies to eradicate chemoresistant disease requires experimental models that recapitulate the het…